214 related articles for article (PubMed ID: 17633093)
1. [Gemtuzumab ozogamicin as monotherapy and combination therapy for acute myelogenous leukemia].
Usui N
Rinsho Ketsueki; 2007 Jun; 48(6):458-67. PubMed ID: 17633093
[No Abstract] [Full Text] [Related]
2. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
Stadtmauer EA
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
[TBL] [Abstract][Full Text] [Related]
3. Gemtuzumab ozogamicin as maintenance therapy after autologous stem cell transplantation in elderly patients with acute myeloid leukaemia.
Cascavilla N; D'Arena G; Greco MM; Melillo L; Merla E; Carella AM
Br J Haematol; 2008 Sep; 142(5):852-3. PubMed ID: 18510691
[No Abstract] [Full Text] [Related]
4. Fractionated administration of gemtuzumab ozogamicin for refractory acute myeloid leukemia.
YAHAGI Y; USUI N; YAMAGUCHI Y; DOBASHI N; YANO S; TAKEI Y; SUGIYAMA K; TAKAHARA S; SAITO T; MINAMI J; KOBAYASHI T; KAMIYAMA Y; MORIKAWA T; AIBA K
Rinsho Ketsueki; 2009 Nov; 50(11):1601-6. PubMed ID: 20009433
[TBL] [Abstract][Full Text] [Related]
5. Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy.
Boyiadzis M; Redner RL; Raptis A; Hou JZ; Agha M; Foon KA
Ann Hematol; 2011 Jun; 90(6):733-5. PubMed ID: 20857113
[No Abstract] [Full Text] [Related]
6. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia.
Oshikawa G; Kakihana K; Saito M; Aoki J; Najima Y; Kobayashi T; Doki N; Sakamaki H; Ohashi K
Br J Haematol; 2015 Jun; 169(5):756-9. PubMed ID: 25522128
[No Abstract] [Full Text] [Related]
7. Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia.
Unal S; Cakir M; Kuşkonmaz B; Cetin M; Tuncer AM
Turk J Pediatr; 2009; 51(1):69-71. PubMed ID: 19378895
[TBL] [Abstract][Full Text] [Related]
8. Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older.
Eom KS; Kim HJ; Min WS; Lee S; Min CK; Cho BS; Kim SY; Kim YJ; Lee DG; Choi SM; Cho SG; Kim DW; Lee JW; Shin WS; Kim CC
Eur J Haematol; 2007 Nov; 79(5):398-404. PubMed ID: 17916082
[TBL] [Abstract][Full Text] [Related]
9. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19).
Amadori S; Suciu S; Selleslag D; Stasi R; Alimena G; Baila L; Rizzoli V; Borlenghi E; Gaidano G; Magro D; Torelli G; Muus P; Venditti A; Cacciola E; Lauria F; Vignetti M; de Witte T
Br J Haematol; 2010 May; 149(3):376-82. PubMed ID: 20230405
[TBL] [Abstract][Full Text] [Related]
11. Gemtuzumab ozogamicin plus cytarabine determines complete remission in acute myeloid leukemia refractory to a double conventional treatment: a case report.
Mele A; Sparaventi G; Guiducci B; Nicolini G; d'Adamo F; Leopardi G; Delfini C; Piccaluga P; Visani G
Haematologica; 2004 Jun; 89(6 Suppl):ECR18. PubMed ID: 15194554
[No Abstract] [Full Text] [Related]
12. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia.
Chowdhury S; Seropian S; Marks PW
Am J Hematol; 2009 Sep; 84(9):599-600. PubMed ID: 19650144
[TBL] [Abstract][Full Text] [Related]
13. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
Sekeres MA; Maciejewski JP; Erba HP; Afable M; Englehaupt R; Sobecks R; Advani A; Seel S; Chan J; Kalaycio ME
Cancer; 2011 Mar; 117(6):1253-61. PubMed ID: 20960521
[TBL] [Abstract][Full Text] [Related]
14. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?
Molnár I; Powell BL
Curr Hematol Malig Rep; 2007 May; 2(2):104-10. PubMed ID: 20425358
[TBL] [Abstract][Full Text] [Related]
15. Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia.
Parigger J; Zwaan CM; Reinhardt D; Kaspers GJ
Expert Rev Anticancer Ther; 2016; 16(2):137-46. PubMed ID: 26646091
[TBL] [Abstract][Full Text] [Related]
16. Molecular response in two children with relapsed acute myeloid leukemia treated with a combination of gemtuzumab ozogamicin and cytarabine.
Brethon B; Auvrignon A; Cayuela JM; Lapillonne H; Leverger G; Baruchel A
Haematologica; 2006 Mar; 91(3):419-21. PubMed ID: 16531270
[TBL] [Abstract][Full Text] [Related]
17. Gemtuzumab ozogamicin plus cytarabine in elderly patients with relapsed or refractory acute myeloid leukaemia.
Doyen J; Italiano A; Peyrade F; Bouyer C; Thyss A
Br J Haematol; 2008 May; 141(5):744-5. PubMed ID: 18373704
[No Abstract] [Full Text] [Related]
18. Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia.
Wang ES; Zeidan A; Tan W; Wilding GE; Ford LA; Wallace PK; Hahn TE; Battiwalla M; McCarthy PL; Wetzler M
Leuk Lymphoma; 2012 Oct; 53(10):2085-8. PubMed ID: 21740302
[No Abstract] [Full Text] [Related]
19. [Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].
Hirayama Y; Terui T; Koike K; Neda H; Ishitani K; Kohda K; Kuroda H; Iyama S; Sato T; Kobune M; Takimoto R; Kato J
Rinsho Ketsueki; 2009 Aug; 50(8):663-5. PubMed ID: 19915382
[TBL] [Abstract][Full Text] [Related]
20. Gemtuzumab ozogamicin: one size does not fit all--the case for personalized therapy.
Ravandi F
J Clin Oncol; 2011 Feb; 29(4):349-51. PubMed ID: 21172885
[No Abstract] [Full Text] [Related]
[Next] [New Search]
